63 related articles for article (PubMed ID: 35156181)
1. Use of a Non-parametric Bayesian Method to Model Health State Preferences: An Application to Polish and Irish EQ-5D-5L Valuations.
Kharroubi SA; Kelleher D
Front Public Health; 2022; 10():917728. PubMed ID: 35812518
[TBL] [Abstract][Full Text] [Related]
2. Do people with different sociodemographic backgrounds value their health differently? Evaluating the role of positional objectivity.
Jyani G; Prinja S; Goyal A; Garg B; Kaur M; Grover S
Front Public Health; 2023; 11():1234320. PubMed ID: 38162609
[TBL] [Abstract][Full Text] [Related]
3. Urban/rural differences in preferences for EQ-5D-5L health states: a study of a multi-ethnic region in China.
Liao M; Luo N; Rand K; Yang Z
Qual Life Res; 2023 Aug; 32(8):2329-2339. PubMed ID: 36944783
[TBL] [Abstract][Full Text] [Related]
4. The Egyptian EQ-5D-5L Extensive Pilot Study: Lessons Learned.
Al Shabasy S; Roudijk B; Abbassi M; Finch A; Stolk E; Farid S
Pharmacoeconomics; 2023 Mar; 41(3):329-338. PubMed ID: 36434416
[TBL] [Abstract][Full Text] [Related]
5. Overview, Update, and Lessons Learned From the International EQ-5D-5L Valuation Work: Version 2 of the EQ-5D-5L Valuation Protocol.
Stolk E; Ludwig K; Rand K; van Hout B; Ramos-Goñi JM
Value Health; 2019 Jan; 22(1):23-30. PubMed ID: 30661630
[TBL] [Abstract][Full Text] [Related]
6. Determinants of Health Preferences Using Data from the Egyptian EQ-5D-5L Valuation Study.
Al Shabasy S; Al Sayah F; Abbassi M; Farid S
Patient; 2022 Sep; 15(5):589-598. PubMed ID: 35156181
[TBL] [Abstract][Full Text] [Related]
7. Determinants of time trade-off valuations for EQ-5D-5L health states: data from the Canadian EQ-5D-5L valuation study.
Sayah FA; Bansback N; Bryan S; Ohinmaa A; Poissant L; Pullenayegum E; Xie F; Johnson JA
Qual Life Res; 2016 Jul; 25(7):1679-85. PubMed ID: 26659899
[TBL] [Abstract][Full Text] [Related]
8. The EQ-5D-5L Valuation Study in Egypt.
Al Shabasy S; Abbassi M; Finch A; Roudijk B; Baines D; Farid S
Pharmacoeconomics; 2022 Apr; 40(4):433-447. PubMed ID: 34786590
[TBL] [Abstract][Full Text] [Related]
9. Experience-Based Swedish TTO and VAS Value Sets for EQ-5D-5L Health States.
Burström K; Teni FS; Gerdtham UG; Leidl R; Helgesson G; Rolfson O; Henriksson M
Pharmacoeconomics; 2020 Aug; 38(8):839-856. PubMed ID: 32307663
[TBL] [Abstract][Full Text] [Related]
10. Preparatory study for the revaluation of the EQ-5D tariff: methodology report.
Mulhern B; Bansback N; Brazier J; Buckingham K; Cairns J; Devlin N; Dolan P; Hole AR; Kavetsos G; Longworth L; Rowen D; Tsuchiya A
Health Technol Assess; 2014 Feb; 18(12):vii-xxvi, 1-191. PubMed ID: 24568945
[TBL] [Abstract][Full Text] [Related]
11. Comparison of different valuation methods for population health status measured by the EQ-5D in three European countries.
Bernert S; Fernández A; Haro JM; König HH; Alonso J; Vilagut G; Sevilla-Dedieu C; de Graaf R; Matschinger H; Heider D; Angermeyer MC;
Value Health; 2009; 12(5):750-8. PubMed ID: 19490564
[TBL] [Abstract][Full Text] [Related]
12. EQ-VT protocol: one-size-fits-all? Challenges and innovative adaptations used in Egypt: a cross-sectional study.
Al Shabasy S; Abbassi M; Farid S
BMJ Open; 2021 Dec; 11(12):e051727. PubMed ID: 34949616
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
